

IPAY 2026

Maximum fair prices through the Medicare Drug Price Negotiation Program

The Inflation Reduction Act (IRA) provides Medicare the ability to directly negotiate the prices of certain high expenditure, single source drugs without generic or biosimilar competition through the Medicare Drug Price Negotiation Program (MDPNP). These negotiated prices, referred to as **Maximum Fair Prices (MFPs)**, are based on agreements reached between the Centers for Medicare and Medicaid Services (CMS) and participating drug manufacturers.

The following outlines the MFP per 30-day equivalent supply (DES) and MFP per package for drugs selected for initial price applicability years (IPAY) 2026, as defined by CMS.

Questions?

For additional information on IPAY 2026 drug pricing or to learn more about CMS' negotiation process for the selected drugs, scan or click the QR code to review CMS resources.



The following list only includes NDCs that are distributed by Cencora. Class of trade restrictions may apply and access to certain products may be determined by the manufacturer.

MFP pricing is provided by CMS and is separate from a product's wholesale acquisition cost (WAC) price. Cencora ordering platforms, including ABC Order, reflect the most current WAC price.

IPAY 2026 MFP products

Product name	Manufacturer name	MFP per 30 DES	NDC-11	Cencora material number	MFP per package	Generic or biosimilar competition?
Eliquis®	Bristol Myers Squibb	\$231.00	00003-0894-31	10112090	\$414.51	No
			00003-0893-31	10112092		
			00003-0893-21	10112091	\$248.70	
			00003-0894-21	10112089		
			00003-0894-70	10177644	\$306.74	
			00003-3764-74	10184632		
Enbrel®	Amgen (listed as Immunex Corporation by CMS)	\$2,355.00	58406-0010-04	10229124	\$1,167.17	No
			58406-0021-04	10229123	\$2,334.48	
			58406-0032-04	10229160	\$2,335.07	
			58406-0044-04	10229148	\$2,334.17	
			58406-0055-04	10237849	\$1,164.88	
Entresto®	Novartis Pharms Corp	\$295.00	00078-1231-20	10291277	\$73.75	Yes
			00078-1238-20	10290932		
			00078-0659-20	10152764	\$313.60	
			00078-0696-20	10152762	\$313.50	
			00078-0777-20	10152763	\$313.52	
			00078-0659-67	10153137	\$940.79	
			00078-0696-67	10153139	\$940.50	
			00078-0777-67	10153134	\$940.57	
Farxiga®	AstraZeneca AB	\$178.50	00310-6210-90	10288508	\$544.76	No
			00310-6205-90	10288535		
			00310-6210-30	10146856	\$181.59	
			00310-6210-39	10275226		
			00310-6205-30	10147921		
			66993-0456-30	10285697		
			66993-0457-30	10285696		
Januvia®	Merck Sharp Dohme	\$113.00	57962-0007-12	10272033	\$6,386.14	No
			57962-0014-28	10241811	\$9,909.99	
			57962-0070-28	10243285	\$9,912.07	
			57962-0140-09	10241706	\$10,620.09	
			57962-0140-12	10245932	\$14,160.12	
			57962-0280-28	10240832	\$9,910.32	
			57962-0420-28	10239706	\$9,911.36	
			57962-0560-28	10248944	\$9,910.97	

¹This drug has been determined to have generic and/or biosimilar competition. Therefore, starting January 1, 2027, this drug will no longer be included in the Medicare Drug Price Negotiation Program and will no longer be subject to maximum fair pricing.

Product name	Manufacturer name	MFP per 30 DES	NDC-11	Cencora material number	MFP per package	Generic or biosimilar competition?
Januvia®	Merck Sharp Dohme	\$113.00	00006-0112-28	10040596		No
			00006-0221-28	10040595	\$390.79	
			00006-0277-28	10051515		
			00006-0112-54	10051156		
			00006-0221-54	10051066	\$351.71	
			00006-0277-54	10051503		
			00006-0221-31	10051062		
			00006-0112-31	10051154	\$117.24	
			00006-0277-31	10051500		
			00006-0277-82	10018387	\$3,907.88	
Jardiance®	Boehringer Ingelheim	\$197.00	00597-0152-30	10142127		No
			00597-0152-37	10158056	\$203.82	
			00597-0153-30	10142129		
			00597-0153-37	10158054		
			00597-0152-90	10142128	\$611.46	
			00597-0153-90	10142160		
Novolog® and Fiasp®	Novo Nordisk Inc	\$119.00	00169-3201-11	10184230	\$69.57	No
			00169-7501-11	10011515		
			00169-3303-12	10011516	\$129.20	
			00169-3205-15	10229177		
			00169-6339-10	10046122	\$134.35	
			00169-3204-15	10184171		
			00169-3206-15	10282846	\$55.66	
			73070-0100-11	10232287	\$34.78	
			73070-0102-15	10232288	\$64.62	
			73070-0103-15	10232269	\$67.18	
Stelara®	Janssen Biotech, Inc.	\$4,695.00	57894-0054-27	10244384	\$652.81	Yes
			57894-0060-02	10245657	\$4,489.82	
			57894-0060-03	10001734		
			57894-0061-03	10001724	\$8,980.14	

¹This drug has been determined to have generic and/or biosimilar competition. Therefore, starting January 1, 2027, this drug will no longer be included in the Medicare Drug Price Negotiation Program and will no longer be subject to maximum fair pricing.

Product name	Manufacturer name	MFP per 30 DES	NDC-11	Cencora material number	MFP per package	Generic or biosimilar competition?
Xarelto®	Janssen Biotech, Inc.	\$197.00	50458-0575-01	10294131	\$206.00	Yes
			50458-0577-60	10191548	\$206.22	
			50458-0578-30	10101349	\$206.25	
			50458-0579-30	10101362	\$206.43	
			50458-0580-30	10098828	\$206.16	
			50458-0577-10	10191572	\$343.71	
			50458-0584-51	10144861	\$349.49	
			50458-0580-90	10184109	\$618.47	
			50458-0577-18	10191554	\$618.67	
			50458-0578-90	10101360	\$618.76	
			50458-0579-90	10101363	\$619.28	
			50458-0580-10	10098829	\$687.19	
			50458-0579-10	10101364	\$688.09	
			50458-0578-10	10101361	\$687.51	
			50458-0579-89	10209413	\$6,880.89	

¹This drug has been determined to have generic and/or biosimilar competition. Therefore, starting January 1, 2027, this drug will no longer be included in the Medicare Drug Price Negotiation Program and will no longer be subject to maximum fair pricing.